NCT05820425

Brief Summary

Neuropsychiatric fluctuations are frequent and debilitating non-motor disorders in Parkinson's disease. Subthalamic stimulation is an effective treatment for motor and non-motor neuropsychiatric fluctuations in Parkinson's disease, which has also allowed to better characterize the electrophysiological activity of the subthalamic nucleus in patients with Parkinson's disease. Numerous studies have been carried out on electrophysiological activity correlated with motor disorders, showing that akinesia is correlated with an abnormal synchronization in the beta frequency band (13-30Hz) in the dorsal motor part of the subnucleus. thalamic. This abnormal synchronization is reduced when the akinesia improves with dopaminergic treatment. On the cognitive-behavioural non-motor side, electrophysiological studies are less numerous, but suggest an involvement of the subthalamic nucleus (with an abnormal synchronization in the lower frequency bands). Currently, the electrophysiological correlates of neuropsychiatric fluctuations are unknown. In addition, all studies on electrophysiological activity are carried out immediately after the intervention, and before the implantation of the pacemaker. It is unknown whether the electrophysiological correlates of motor and non-motor fluctuations change following their transient improvement observed in the setting of chronic stimulation of the subthalamic nucleus and chronic reduction of dopaminergic treatment. The new PERCEPT stimulators (Medtronic) available on the market make it possible to record long-term electrophysiological activity for the first time. With this study we want to define the electrophysiological markers of neuropsychiatric fluctuations and their change over time.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
12

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 6, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

April 7, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 19, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2026

Completed
Last Updated

June 3, 2024

Status Verified

May 1, 2024

Enrollment Period

1.8 years

First QC Date

March 6, 2023

Last Update Submit

May 31, 2024

Conditions

Keywords

Local Field PotentialsNeuropsychiatric Fluctuations ScaleSubthalamic nucleus stimulation

Outcome Measures

Primary Outcomes (3)

  • The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON

    Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV\^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.

    in the 10 days following surgery

  • The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON

    Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV\^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.

    at 3 months after surgery

  • The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON

    Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV\^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.

    at 1 year after surgery

Study Arms (1)

Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS

Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS, using PERCEPT device (Medtronic)

Other: LFP and EEG recording

Interventions

STN LFP and EEG recording during the OFF and ON medication condition

Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS

Eligibility Criteria

Age30 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

PD patients with motor and non motor fluctuations, operated within the last 10 days for STN stimulation (PERCEPT implant)

You may qualify if:

  • Age between 30 and 75 years
  • Diagnosis of Parkinson's disease with fluctuations and/or dyskinesias
  • Ability to collaborate and fill a questionnaire in the OFF state condition (this criterion will be assessed based on the results of the preoperative screening to retain indication for STN stimulation, which takes place whenever a PD patient has to undergo DBS surgery)
  • Surgery for bilateral STN stimulation with a Percept® (Medtronic) in the last 10 days
  • Absence of dementia (defined as MoCA score \> 24)

You may not qualify if:

  • Active psychosis
  • Patients unable to provide an informed consent or under gardianship
  • Patients under judicial supervision or deprived of liberty
  • Pregnancy and breastfeeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Grenoble Alpes

Grenoble, 38043, France

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • Anna Castrioto, MD, PhD

    CHU Grenoble Alpes

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Pierre Pelissier, MsC

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 6, 2023

First Posted

April 19, 2023

Study Start

April 7, 2023

Primary Completion

February 1, 2025

Study Completion

February 1, 2026

Last Updated

June 3, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations